Key result
The N291S polymorphism of the LPL gene was present in 9.7% of patients with familial combined hyperlipidemia and was significantly associated with the atherogenic pattern B LDL (87.5% vs 30.8% in non-carriers).
Why the study?
Does the N291S polymorphism of the LPL gene associate with small and dense LDL (pattern B) and an atherogenic lipid profile in patients with familial combined hyperlipidemia?
Case-Control (n=379)
No
Does the N291S polymorphism of the LPL gene associate with small and dense LDL (pattern B) and an atherogenic lipid profile in patients with familial combined hyperlipidemia?
N291S may link to pattern B LDL in FCH; hypothesis-generating and should not yet change practice.
There is a predominance of small and dense LDL cholesterol particles in familial combined hyperlipidemia (FCH). The lipoprotein lipase gene could exert an influence in these circumstances.To study the relationship of pattern B LDL and lipids with N291S polymorphism of lipoprotein lipase (LPL) in FCH patients.Lipid profile, apolipoproteins, diameter of LDL and N291S polymorphism were determined in 93 patients with FCH and 286 individuals from the general population.FCH patients with N291S polymorphism showed a lower mean diameter of LDL. FCH patients with pattern B LDL showed higher concentrations of triglycerides, VLDLc, non-HDLc and apo B100 and lower levels of HDLc than those with pattern A. Of FCH patients with polymorphism 87.5% presented pattern B and 12.5% pattern A, while patients without polymorphism presented pattern A in 69.2% cases and pattern B in 30.8% cases, with differences being statistically significant (p < 0.004). The prevalence of this mutation in our FCH patients was 9.7%.The prevalence of N291S mutation in our FCH patients was similar to the 9.3% described in Dutch FCHL patients but clearly higher than the 2-5% described for other Caucasian populations. No polymorphism was found in our general population sample. FCH patients with phenotype B of LDL possessed an atherogenic lipid profile. The relationship between small and dense LDL and the presence of the N291S mutation may identify patients with high cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
López‐Ruiz et al. (2009) conducted a case-control in Familial Combined Hyperlipidemia (n=379). N291S polymorphism of the LPL gene vs. Non-carriers of the polymorphism was evaluated on Prevalence of pattern B LDL (p=<0.004). The N291S polymorphism of the LPL gene was present in 9.7% of patients with familial combined hyperlipidemia and was significantly associated with the atherogenic pattern B LDL (87.5% vs 30.8% in non-carriers).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: